Navigation Links
Harms Trabeculotomy Probe, right

ProductsHarms Trabeculotomy Probe, right
Company Katena Products, Inc.
Item Harms Trabeculotomy Probe, right
Features Katena is world renowned for:
  • producing instruments of consistently excellent quality that have become the industry standard.
  • providing unexcelled service to its customers and strong support for its distributors worldwide.
  • developing innovative instruments for new surgical techniques and advances in the field of ophthalmology
Description Katena Products, Inc. is the largest independently owned American company dedicated exclusively to ophthalmic surgical instrumentation. Katena offers its products to over 7,000 customers in the United States and, through a global network of distributors, to customers in more than 100 countries around the world.
Info Katena Products, Inc.
Customer Service: (800) 225-1195
Web site: http://www.katena.com/

Related medicine products :

1. Harms Corneal Utility Forceps, Colibri Style
2. Harms-Tubingen Straight Tying Forceps
3. Harms-Tubingen Curved Tying Forceps
4. Harms tying forceps
5. Harms-Tuebingen Tying Forceps
6. Harms Trabeculotomy Probe, left
7. Endophotocoagulation Probe, Fully Reusable, Autoclavable
8. Illuminated Laser Probe, Wide Field, Fully Reusable, Autoclavable
9. Wide Field Illumination Probe, Fully Reusable, Autoclavable
10. Probe, Small Joint Hook Tip
11. Insulated Suction/Coagulation Probe, dual-incision
Other Medicine News:Health News:Know the Warning Signs of Stroke 2Health News:Know the Warning Signs of Stroke 3Health News:Know the Warning Signs of Stroke 4Health News:Researchers find roadmap to next-generation cancer therapies 2Health News:Americans believe wounded Iraq war veterans are not receiving high quality medical care in US 2Health News:Americans believe wounded Iraq war veterans are not receiving high quality medical care in US 3Health News:Drowsy Drivers Make Holiday Weekend Among the Most Dangerous 2Health News:Video: GlaxoSmithKline Consumer Healthcare Offers Free Nicotine Lozenges for All Certified Pilots and Air Traffic Controllers to Help Them Safely Quit Smoking 2Health News:Video: GlaxoSmithKline Consumer Healthcare Offers Free Nicotine Lozenges for All Certified Pilots and Air Traffic Controllers to Help Them Safely Quit Smoking 3Health News:Video: GlaxoSmithKline Consumer Healthcare Offers Free Nicotine Lozenges for All Certified Pilots and Air Traffic Controllers to Help Them Safely Quit Smoking 4
Breaking Medicine Technology:Medco, State of Illinois and Community Retail Pharmacies Launch 'Wired' Collaborative Solution to Close Critical Medication-Related Gaps in Healthcare, Improving Outcomes and Lowering Costs 2Medco, State of Illinois and Community Retail Pharmacies Launch 'Wired' Collaborative Solution to Close Critical Medication-Related Gaps in Healthcare, Improving Outcomes and Lowering Costs 3Medco, State of Illinois and Community Retail Pharmacies Launch 'Wired' Collaborative Solution to Close Critical Medication-Related Gaps in Healthcare, Improving Outcomes and Lowering Costs 4Medco, State of Illinois and Community Retail Pharmacies Launch 'Wired' Collaborative Solution to Close Critical Medication-Related Gaps in Healthcare, Improving Outcomes and Lowering Costs 5FDA Launches Orphan Drug Workshop at KGI 2Sangamo BioSciences Announces Presentation of Preliminary Data From Phase 2 Study of SB-509 at International ALS Symposium 2Sangamo BioSciences Announces Presentation of Preliminary Data From Phase 2 Study of SB-509 at International ALS Symposium 3Sangamo BioSciences Announces Presentation of Preliminary Data From Phase 2 Study of SB-509 at International ALS Symposium 4Sangamo BioSciences Announces Presentation of Preliminary Data From Phase 2 Study of SB-509 at International ALS Symposium 5Sangamo BioSciences Announces Presentation of Preliminary Data From Phase 2 Study of SB-509 at International ALS Symposium 6Researchers prolong the plasma half life of biopharmaceutical proteins 14192 1Researchers prolong the plasma half life of biopharmaceutical proteins 14192 2Pivotal Registration Trial of OPAXIO Maintenance Therapy in First Line Ovarian Cancer Reaches Enrollment Milestone of 600 patients Cell Therapeutics 5026 1Pivotal Registration Trial of OPAXIO Maintenance Therapy in First Line Ovarian Cancer Reaches Enrollment Milestone of 600 patients Cell Therapeutics 5026 2Pivotal Registration Trial of OPAXIO Maintenance Therapy in First Line Ovarian Cancer Reaches Enrollment Milestone of 600 patients Cell Therapeutics 5026 3Pivotal Registration Trial of OPAXIO Maintenance Therapy in First Line Ovarian Cancer Reaches Enrollment Milestone of 600 patients Cell Therapeutics 5026 4Fortebio Inc to Present at UBS Global Life Sciences Conference 14190 1